IMCR Immunocore Holdings plc

NASDAQ
$34.21

Immunocore Holdings plc (IMCR) is expected to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $0.07 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +4.2% since its last earnings release on August 6, 2026.

Immunocore Holdings plc Missed Consensus Estimates
Thursday, August 6, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 7:00 AM ET
Earnings Whisper
-
vs ($0.07)
Rev est $118.53M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $34.28

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Immunocore Holdings plc

Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow